Key Points
- Semaglutide has reduced alcohol craving and several measures of heavy drinking in early randomized clinical trials.
- A 2026 trial involving 108 people with alcohol use disorder and obesity found significantly greater reductions in heavy drinking among participants receiving semaglutide plus therapy compared with therapy plus placebo.
- Another 2026 trial found mixed results: oral semaglutide did not significantly improve its primary laboratory measure of alcohol craving, but participants experienced fewer heavy drinking days and reported lower real-world cravings.
- Semaglutide is not FDA-approved for alcohol use disorder. Naltrexone, acamprosate, and disulfiram remain the three medications specifically approved in the United States for AUD.
- Ozempic does not treat alcohol withdrawal. Someone who has developed physical alcohol dependence may need medical detox before attempting to stop drinking.
- Brooks Healing Center provides alcohol addiction treatment in Tennessee, including medical detox, residential care, medication-assisted treatment, PHP, IOP, and sober living support based on each person’s needs.
Reports that people taking Ozempic suddenly lose interest in alcohol have circulated for several years. Some people describe pouring a drink and barely touching it. Others say alcohol simply does not seem as appealing as it once did.
Those experiences initially sounded anecdotal. Now, researchers have begun testing whether there is actually something behind them.
The answer so far is promising, but not definitive.
Semaglutide, the active medication in Ozempic and Wegovy, has reduced alcohol cravings, heavy drinking, or the amount consumed in several randomized clinical trials. At the same time, not every alcohol-related outcome has improved, the studies remain relatively small, and semaglutide is not currently FDA-approved to treat alcohol use disorder (AUD).
Understanding that distinction matters, especially for people wondering whether Ozempic could replace established alcohol addiction treatment.
First, Is This Actually Research on Ozempic?
Not exactly.
Ozempic is a brand name for semaglutide, a glucagon-like peptide-1 receptor agonist, commonly shortened to GLP-1 receptor agonist.
Ozempic is FDA-approved for certain adults with type 2 diabetes and for reducing specific cardiovascular and kidney risks in qualifying patients. Alcohol use disorder is not among its approved indications.
Semaglutide is also sold under other brand names and formulations. For example, Wegovy contains semaglutide and is primarily associated with weight management.
Therefore, headlines saying that researchers are studying “Ozempic for alcoholism” are somewhat imprecise. Researchers are investigating whether semaglutide and the broader GLP-1 class could eventually have a role in addiction treatment.
That research has become considerably more interesting over the past two years.
Why Would a Weight-Loss or Diabetes Medication Affect Alcohol Cravings?
GLP-1 medications are best known for reducing appetite and helping people feel full.
But appetite is not their only potential effect.
GLP-1 systems also interact with areas of the brain involved in motivation and reward. Researchers have therefore questioned whether medications capable of decreasing the motivational pull of highly rewarding foods might also influence alcohol and other addictive substances.
NIH researchers have noted that GLP-1 medications affect pathways involved in appetite regulation and reward, which may help explain reports of reduced desire for alcohol.
The exact mechanism is not settled.
Reduced drinking could involve changes in reward signaling, craving, satiety, or the reinforcing effects of alcohol. Some effects may also be indirect. For example, nausea or decreased appetite could temporarily make drinking less appealing.
The important point is that researchers are finding a signal strong enough to test in controlled trials rather than relying solely on anecdotes.
What Did the First Semaglutide Alcohol Trial Find?
One of the most important early trials was published in JAMA Psychiatry in 2025.
Researchers randomized 48 adults with alcohol use disorder to receive either low-dose injectable semaglutide or placebo for nine weeks.
The participants were not actively seeking alcohol treatment, which is an important limitation.
After treatment, the semaglutide group consumed significantly less alcohol during a controlled laboratory drinking session.
Researchers also found reductions in:
- Weekly alcohol craving
- Drinks consumed per drinking day
- Heavy drinking over time
However, semaglutide did not significantly reduce the total number of drinking days or average drinks per calendar day.
That distinction is important.
The study did not show that semaglutide simply made people stop drinking. Instead, the results suggested that people taking semaglutide may drink less heavily when they do drink and may experience less craving.
Because only 48 people participated, the researchers concluded that larger clinical trials were needed.
Those larger studies have now started appearing.
The 2026 Lancet Trial Produced Stronger Results
In May 2026, The Lancet published a randomized, double-blind trial involving 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity.
Participants received either once-weekly semaglutide or placebo for 26 weeks. Importantly, both groups were also offered cognitive behavioral therapy for AUD.
That means researchers were not testing medication instead of addiction treatment. They were testing whether adding semaglutide provided an additional benefit.
It did.
Heavy drinking days decreased by approximately 41 percentage points from baseline in the semaglutide group compared with about 26 percentage points in the placebo group. The estimated difference between the groups was 13.7 percentage points.
Researchers also reported greater improvements in measures including:
- Total alcohol consumption
- Drinks per drinking day
- Alcohol craving
- Harmful alcohol use
- Alcohol-related biomarkers
The most commonly reported adverse effects were temporary gastrointestinal problems such as nausea, constipation, diarrhea, reduced appetite, reflux, and abdominal discomfort.
The findings provided considerably stronger support for the possibility that semaglutide could eventually become part of AUD treatment.
There was still an important limitation, though: every participant in the study had both AUD and obesity.
We cannot assume that the same effect will occur in people without obesity.
Another 2026 Study Shows Why We Shouldn’t Get Ahead of the Research
A second randomized trial published online in The American Journal of Psychiatry in July 2026 provides a useful reality check.
Researchers studied 50 treatment-seeking adults with moderate-to-severe AUD who received either oral semaglutide or placebo for eight weeks.
The primary goal was to determine whether semaglutide reduced alcohol craving triggered by alcohol-related cues in a laboratory setting.
On that primary outcome, semaglutide did not significantly outperform placebo.
It also did not significantly reduce the overall number of drinks per day.
However, semaglutide did significantly reduce:
- Heavy drinking days
- Drinks consumed per drinking day
- Alcohol cravings measured outside the laboratory
- Alcohol-related negative consequences
More participants receiving semaglutide also moved into a lower World Health Organization drinking-risk category.
Rather than disproving the earlier research, these results suggest that semaglutide’s effect may be more complicated than simply “turning off” alcohol cravings.
Across the trials so far, one of the more consistent signals appears to be less heavy drinking and less alcohol consumed during drinking episodes.
Observational Studies Point in the Same Direction
Clinical trials are not the only reason researchers became interested in semaglutide for alcohol use disorder.
A 2024 Nature Communications study analyzed electronic health records from large populations of people who had been prescribed semaglutide for obesity or type 2 diabetes.
Among people with obesity, semaglutide use was associated with approximately a 50% to 56% lower risk of a new or recurrent AUD diagnosis compared with several other medications. Similar associations appeared in a separate population of people with type 2 diabetes.
Those numbers sound dramatic, but observational research cannot establish cause and effect.
People prescribed semaglutide may differ from other patients in ways researchers cannot completely account for. That is why randomized clinical trials such as the 2025 and 2026 studies are so important.
What makes the overall research interesting is that several different types of evidence are beginning to point in roughly the same direction.
Does Semaglutide Work Like Naltrexone?
Not exactly.
Naltrexone is an established medication for alcohol use disorder that interacts with opioid receptors involved in alcohol’s rewarding effects.
Semaglutide works primarily through GLP-1 pathways and is still being investigated as an AUD treatment.
Currently, the FDA has approved three medications specifically for alcohol use disorder:
- Naltrexone can reduce alcohol’s rewarding effects, cravings, and the likelihood of heavy drinking.
- Acamprosate can help people maintain abstinence after stopping alcohol.
- Disulfiram produces an unpleasant physical reaction when alcohol is consumed and can help some individuals maintain abstinence.
Other medications may sometimes be prescribed off-label depending on a person’s history and clinical needs.
At Brooks Healing Center, medication decisions for alcohol use disorder are individualized and integrated with behavioral and recovery support rather than viewed as a replacement for treatment. Brooks currently provides medication-assisted treatment options for AUD alongside other levels of addiction care.
Could Semaglutide Eventually Become an Alcohol Addiction Medication?
Potentially.
There is now enough evidence to take the possibility seriously.
The progression is notable:
- Anecdotal reports suggested that people using GLP-1 medications sometimes lost interest in alcohol.
- Observational studies subsequently found lower rates of AUD diagnoses among people receiving semaglutide.
- A 2025 randomized trial found reductions in alcohol craving and several drinking measures.
- A larger 2026 trial found meaningful reductions in heavy drinking among people with AUD and obesity receiving semaglutide alongside therapy.
- Another 2026 randomized trial produced more mixed results but again found reductions in heavy drinking and several real-world alcohol outcomes.
That is substantially more evidence than a collection of social media stories.
It is still not enough to make semaglutide a standard AUD medication.
Researchers need larger and more diverse studies to determine:
- Which patients benefit most
- Whether benefits occur regardless of body weight
- Which dose and formulation work best
- How long treatment should continue
- Whether benefits persist after semaglutide is discontinued
- How semaglutide compares directly with medications such as naltrexone
- Whether combining GLP-1 medications with existing AUD medications provides additional benefit
- The long-term safety and effectiveness of using these medications specifically for addiction
Ozempic Is Not a Treatment for Alcohol Withdrawal
There is another critical distinction.
Reducing alcohol craving is not the same thing as safely treating alcohol withdrawal.
Someone who has been drinking heavily or consistently can develop physical dependence. Abruptly stopping alcohol may cause symptoms ranging from anxiety, shaking, nausea, sweating, and insomnia to seizures and severe withdrawal complications.
Semaglutide does not replace medical detox.
Someone who thinks they may be physically dependent on alcohol should receive a medical evaluation before attempting to suddenly stop drinking.
Brooks Healing Center provides medical detox in Tennessee with 24/7 access to medical and clinical support during alcohol withdrawal, followed by residential and continuing levels of care when appropriate.
The Bottom Line: Can Ozempic Reduce Alcohol Cravings?
Semaglutide appears capable of reducing alcohol craving for some people, and multiple clinical trials now suggest it may also decrease heavy drinking and the amount of alcohol consumed.
But saying “Ozempic treats alcoholism” goes beyond what the evidence currently supports.
Semaglutide is not FDA-approved for AUD, research remains relatively early, and some trial outcomes have been mixed. The strongest evidence so far suggests it could eventually become another tool within comprehensive alcohol addiction treatment—not a replacement for detox, therapy, recovery support, or medications that are already proven for AUD.
The research is worth watching.
For someone struggling with alcohol today, however, there is no reason to wait for the next medication to be developed.
Alcohol Addiction Treatment at Brooks Healing Center
Alcohol use disorder affects far more than whether someone experiences a craving. Treatment may need to address physical dependence, withdrawal risk, mental health, relationships, triggers, coping skills, relapse patterns, and the circumstances that keep alcohol use going.
Brooks Healing Center in Tennessee provides an individualized continuum of addiction care that includes medical detox, residential treatment, medication-assisted treatment, partial hospitalization programming, intensive outpatient programming, and sober living support.
If drinking has become difficult to control, or stopping alcohol causes withdrawal symptoms, talk with the Brooks Healing Center admissions team about what level of support may be appropriate.
Call Brooks Healing Center at (931) 486-8824 to discuss alcohol addiction treatment in Tennessee.
This article is intended for educational purposes and should not be considered individualized medical advice. Medication decisions should be made with a qualified medical professional.
Frequently Asked Questions About Ozempic and Alcohol
Does Ozempic help with alcohol cravings?
Early research suggests that semaglutide, the active ingredient in Ozempic, may reduce alcohol cravings and heavy drinking in some people. A 2025 randomized trial found reduced weekly alcohol craving and drinks per drinking day, while 2026 studies also found reductions in heavy drinking and some real-world craving measures. However, results have not been consistent across every outcome, and Ozempic is not FDA-approved to treat alcohol use disorder.
Can you drink alcohol on Ozempic?
Alcohol is not listed as an absolute contraindication to Ozempic, but whether it is appropriate to drink depends on your health, medications, diabetes control, and drinking history. Alcohol can contribute to low blood sugar in some people and may complicate gastrointestinal symptoms or dehydration associated with semaglutide. Anyone taking Ozempic should discuss alcohol use with their prescribing healthcare provider.
For someone struggling with alcohol use disorder, the more important question may be whether drinking itself has become difficult to control rather than whether alcohol can technically be combined with Ozempic.
Does alcohol affect Ozempic?
Alcohol does not necessarily prevent Ozempic from working, but drinking can complicate treatment. Alcohol can affect blood sugar and may increase the risk of hypoglycemia in certain circumstances, particularly for people with diabetes who take other glucose-lowering medications. Semaglutide can also cause nausea, vomiting, and other gastrointestinal effects, making individual medical guidance important.
Interestingly, current research is also examining the relationship in the opposite direction: whether semaglutide itself changes the desire to drink alcohol. Clinical trials have found reductions in heavy drinking and certain measures of alcohol craving among participants taking semaglutide.
How much alcohol can you drink on Ozempic?
There is no single amount of alcohol that is considered safe for everyone taking Ozempic. The appropriate amount depends on factors such as diabetes control, other medications, medical conditions, and an individual’s relationship with alcohol. A healthcare provider who knows your medical history can provide individualized guidance.
For people with alcohol use disorder or physical alcohol dependence, attempting to simply limit drinking while taking Ozempic should not be considered a substitute for addiction treatment. Semaglutide does not treat potentially dangerous alcohol withdrawal, and people who experience withdrawal symptoms may require medically supervised detox.
Sources
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
Klausen, M. K., Justesen, S. K., Pedersen, J. N., Rasmussen, L., Jensen, A., Jensen, M. E., Knorr, U. B., Bergmann, M. L., Holst, J. J., Hartmann, B., Koob, G. F., Benveniste, H., Volkow, N. D., Ekstrøm, C. T., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial. The Lancet, 407(10540), 1687–1698.
https://www.sciencedirect.com/science/article/pii/S0140673626003053
Schacht, J. P., Sakai, J. T., Raymond, K., & Shelton, R. (2026). Oral semaglutide for alcohol use disorder: A randomized clinical trial. American Journal of Psychiatry. Advance online publication.
https://psychiatryonline.org/doi/full/10.1176/appi.ajp.20260003
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications, 15, Article 4548.
https://www.nature.com/articles/s41467-024-48780-6
National Institute on Alcohol Abuse and Alcoholism. (n.d.). Treatment for alcohol problems: Finding and getting help. National Institutes of Health.
https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help
National Institute on Alcohol Abuse and Alcoholism. (n.d.). Understanding alcohol use disorder. National Institutes of Health.
https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder
National Institutes of Health. (2026, May 12). GLP-1 plus therapy can reduce heavy drinking.
https://www.nih.gov/news-events/nih-research-matters/glp-1-plus-therapy-can-reduce-heavy-drinking
U.S. Food and Drug Administration. (2025). Ozempic (semaglutide) injection: Prescribing information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf
